Immunocore Holdings plc released a corporate presentation outlining updates on its bispecific soluble T cell receptor platform across oncology, infectious diseases and autoimmune diseases. The presentation highlights KIMMTRAK (tebentafusp-tebn) as approved for metastatic uveal melanoma and describes additional development programs, including the Phase 3 TEBE-AM trial in second-line or later advanced cutaneous melanoma and the Phase 3 ATOM adjuvant uveal melanoma trial led by the European Organisation for Research and Treatment of Cancer. It also provides an overview of the PRAME-targeted portfolio, including brenetafusp and the ongoing Phase 3 PRISM-MEL-301 trial in first-line advanced cutaneous melanoma. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunocore Holdings plc published the original content used to generate this news brief on February 25, 2026, and is solely responsible for the information contained therein.